AAAAAA
Results:
1-10
|
Results: 10
Authors:
Dumez, H
Guetens, G
De Boeck, G
Highley, M
Tjaden, UR
Maes, R
Hanauske, A
Van Oosterom, AT
de Bruijn, EA
Citation: H. Dumez et al., Quantitation of suspensions (MESED). Application of MESED-GC/MS in the quantitation of ifosfamide mustard in erythrocytes, plasma, and plasma water, J SEP SCI, 24(2), 2001, pp. 123-128
Authors:
Vermorken, JB
Mangioni, C
Pecorelli, S
Van Der Burg, MEL
Van Oosterom, AT
Huinink, WWT
Rotmensz, N
Dalesio, O
Citation: Jb. Vermorken et al., Phase II study of vincristine, bleomycin, mitomycin C and cisplatin (VBMP)in disseminated squamous cell carcinoma of the uterine cervix, INT J GYN C, 10(5), 2000, pp. 358-365
Authors:
Favalli, G
Vermorken, JB
Vantongelen, K
Renard, J
Van Oosterom, AT
Pecorelli, S
Citation: G. Favalli et al., Quality control in multicentric clinical trials. An experience of the EORTC gynecological cancer cooperative group, EUR J CANC, 36(9), 2000, pp. 1125-1133
Authors:
Schrijvers, D
Pronk, L
Highley, M
Bruno, R
Locci-Tonelli, D
De Bruijn, E
Van Oosterom, AT
Verweij, J
Citation: D. Schrijvers et al., Pharmacokinetics of ifosfamide are changed by combination with docetaxel -Results of a phase I pharmacologic study, AM J CL ONC, 23(4), 2000, pp. 358-363
Authors:
Zhou, HH
Choi, L
Lau, H
Bruntsch, U
De Vries, EEGE
Eckhardt, G
Van Oosterom, AT
Verweij, J
Schran, H
Barbet, N
Linnartz, R
Capdeville, R
Citation: Hh. Zhou et al., Population pharmacokinetics/toxicodynamics (PK/TD) relationship of SAM486Ain phase I studies in patients with advanced cancers, J CLIN PHAR, 40(3), 2000, pp. 275-283
Authors:
D'hondt, R
Thomas, J
Van Oosterom, AT
Dewolf-Peeters, C
Citation: R. D'Hondt et al., Hodgkin's disease in a patient with von Hippel-Landau disease. A case report, ACT CLIN B, 55(5), 2000, pp. 276-278
Authors:
Schrijvers, D
Catimel, G
Highley, M
Hoppener, FJP
Dirix, L
De Bruijn, E
Droz, JP
Van Oosterom, AT
Citation: D. Schrijvers et al., KW-2149-induced pulmonary toxicity is not prevented by corticosteroids: a phase I and pharmacokinetic study, ANTI-CANC D, 10(7), 1999, pp. 633-639
Authors:
Schrijvers, D
Highley, R
De Bruyn, E
Van Oosterom, AT
Vermorken, JB
Citation: D. Schrijvers et al., Role of red blood cells in pharmacokinetics of chemotherapeutic agents, ANTI-CANC D, 10(2), 1999, pp. 147-153
Authors:
Van Der Heyden, SAM
Highley, MS
De Bruijn, EA
Tjaden, UR
Reeuwijk, HJEM
Van Slooten, H
Van Oosterom, AT
Maes, RAA
Citation: Sam. Van Der Heyden et al., Pharmacokinetics and bioavailability of oral 5 '-deoxy-5-fluorouridine in cancer patients, BR J CL PH, 47(4), 1999, pp. 351-356
Authors:
Boffetta, P
Van Oosterom, AT
Henry-Amar, M
Kyrtopoulos, SA
Boyle, P
Simonato, L
Van Leeuwen, F
Shuker, D
Swerdlow, A
Zaridze, DG
Citation: P. Boffetta et al., Markers of DNA damage and risk of second malignancy following chemotherapy, BIOM HLTH R, 24, 1998, pp. 359-361
Risultati:
1-10
|